AustralieFrV1, Ncbi, Checkpoint, bibRecord, 004C06

Clinical Similarity of the Biosimilar ABP 501 Compared With Adalimumab After Single Transition: Long-Term Results From a Randomised, Double-Blind, 52-Week, Phase 3 Study in Moderate-to-Severe Plaque Psoriasis Patients.

Identifieur interne : 004C06 ( Ncbi/Checkpoint ); précédent : 004C05; suivant : 004C07

Clinical Similarity of the Biosimilar ABP 501 Compared With Adalimumab After Single Transition: Long-Term Results From a Randomised, Double-Blind, 52-Week, Phase 3 Study in Moderate-to-Severe Plaque Psoriasis Patients.

Auteurs : K. Papp [Canada] ; H. Bachelez [France] ; A. Costanzo [Italie] ; P. Foley [Australie] ; M. Gooderham [Canada] ; P. Kaur [États-Unis] ; S. Philipp [Allemagne] ; L. Spelman [Australie] ; N. Zhang [États-Unis] ; B. Strober [États-Unis]

Source :

The British journal of dermatology [ 1365-2133 ] ; 2017.

RBID : pubmed:28755394

Abstract

ABP 501, an FDA- and EMA-approved biosimilar, is highly similar to adalimumab in structure, function, and pharmacokinetics.

DOI: 10.1111/bjd.15857
PubMed: 28755394

Affiliations:

Allemagne, Australie, Canada, France, Italie, États-Unis
Berlin, Californie, Connecticut, Victoria (État), Île-de-France
Berlin, Melbourne, Paris
Université de Melbourne

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000939
to stream PubMed, to step Curation: 000936
to stream PubMed, to step Checkpoint: 000936
to stream Ncbi, to step Merge: 004C06
to stream Ncbi, to step Curation: 004C06

Links to Exploration step

pubmed:28755394

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical Similarity of the Biosimilar ABP 501 Compared With Adalimumab After Single Transition: Long-Term Results From a Randomised, Double-Blind, 52-Week, Phase 3 Study in Moderate-to-Severe Plaque Psoriasis Patients.</title>
<author><name sortKey="Papp, K" sort="Papp, K" uniqKey="Papp K" first="K" last="Papp">K. Papp</name>
<affiliation wicri:level="1"><nlm:affiliation>Clinical Research and Probity Medical Research, Waterloo, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Clinical Research and Probity Medical Research, Waterloo, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bachelez, H" sort="Bachelez, H" uniqKey="Bachelez H" first="H" last="Bachelez">H. Bachelez</name>
<affiliation wicri:level="3"><nlm:affiliation>Sorbonne Paris Cité Université Paris Diderot, Department of Dermatology, AP-HP HP Hôpital Saint-Louis, INSERM U1163, Institut Imagine, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Sorbonne Paris Cité Université Paris Diderot, Department of Dermatology, AP-HP HP Hôpital Saint-Louis, INSERM U1163, Institut Imagine, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Costanzo, A" sort="Costanzo, A" uniqKey="Costanzo A" first="A" last="Costanzo">A. Costanzo</name>
<affiliation wicri:level="1"><nlm:affiliation>Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Rozzano - Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Rozzano - Milan</wicri:regionArea>
<wicri:noRegion>Rozzano - Milan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Foley, P" sort="Foley, P" uniqKey="Foley P" first="P" last="Foley">P. Foley</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine (Dermatology), The University of Melbourne, St Vincent's Hospital Melbourne, Skin& Cancer Foundation Inc, and Probity Medical Research, Carlton, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Medicine (Dermatology), The University of Melbourne, St Vincent's Hospital Melbourne, Skin& Cancer Foundation Inc, and Probity Medical Research, Carlton</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gooderham, M" sort="Gooderham, M" uniqKey="Gooderham M" first="M" last="Gooderham">M. Gooderham</name>
<affiliation wicri:level="1"><nlm:affiliation>SKiN Centre for Dermatology and Probity Medical Research, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>SKiN Centre for Dermatology and Probity Medical Research, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kaur, P" sort="Kaur, P" uniqKey="Kaur P" first="P" last="Kaur">P. Kaur</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc, Thousand Oaks, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Philipp, S" sort="Philipp, S" uniqKey="Philipp S" first="S" last="Philipp">S. Philipp</name>
<affiliation wicri:level="3"><nlm:affiliation>Psoriasis Research and Treatment Center, University Hospital Charité, Berlin, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Psoriasis Research and Treatment Center, University Hospital Charité, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Spelman, L" sort="Spelman, L" uniqKey="Spelman L" first="L" last="Spelman">L. Spelman</name>
<affiliation wicri:level="1"><nlm:affiliation>Veracity Clinical Research and Probity Medical Research, Woolloongabba, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Veracity Clinical Research and Probity Medical Research, Woolloongabba, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zhang, N" sort="Zhang, N" uniqKey="Zhang N" first="N" last="Zhang">N. Zhang</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc, Thousand Oaks, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Strober, B" sort="Strober, B" uniqKey="Strober B" first="B" last="Strober">B. Strober</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Connecticut Health Center and Probity Medical Research, Farmington, CT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Connecticut Health Center and Probity Medical Research, Farmington, CT</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28755394</idno>
<idno type="pmid">28755394</idno>
<idno type="doi">10.1111/bjd.15857</idno>
<idno type="wicri:Area/PubMed/Corpus">000939</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000939</idno>
<idno type="wicri:Area/PubMed/Curation">000936</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000936</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000936</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000936</idno>
<idno type="wicri:Area/Ncbi/Merge">004C06</idno>
<idno type="wicri:Area/Ncbi/Curation">004C06</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004C06</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical Similarity of the Biosimilar ABP 501 Compared With Adalimumab After Single Transition: Long-Term Results From a Randomised, Double-Blind, 52-Week, Phase 3 Study in Moderate-to-Severe Plaque Psoriasis Patients.</title>
<author><name sortKey="Papp, K" sort="Papp, K" uniqKey="Papp K" first="K" last="Papp">K. Papp</name>
<affiliation wicri:level="1"><nlm:affiliation>Clinical Research and Probity Medical Research, Waterloo, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Clinical Research and Probity Medical Research, Waterloo, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bachelez, H" sort="Bachelez, H" uniqKey="Bachelez H" first="H" last="Bachelez">H. Bachelez</name>
<affiliation wicri:level="3"><nlm:affiliation>Sorbonne Paris Cité Université Paris Diderot, Department of Dermatology, AP-HP HP Hôpital Saint-Louis, INSERM U1163, Institut Imagine, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Sorbonne Paris Cité Université Paris Diderot, Department of Dermatology, AP-HP HP Hôpital Saint-Louis, INSERM U1163, Institut Imagine, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Costanzo, A" sort="Costanzo, A" uniqKey="Costanzo A" first="A" last="Costanzo">A. Costanzo</name>
<affiliation wicri:level="1"><nlm:affiliation>Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Rozzano - Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Rozzano - Milan</wicri:regionArea>
<wicri:noRegion>Rozzano - Milan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Foley, P" sort="Foley, P" uniqKey="Foley P" first="P" last="Foley">P. Foley</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine (Dermatology), The University of Melbourne, St Vincent's Hospital Melbourne, Skin& Cancer Foundation Inc, and Probity Medical Research, Carlton, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Medicine (Dermatology), The University of Melbourne, St Vincent's Hospital Melbourne, Skin& Cancer Foundation Inc, and Probity Medical Research, Carlton</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gooderham, M" sort="Gooderham, M" uniqKey="Gooderham M" first="M" last="Gooderham">M. Gooderham</name>
<affiliation wicri:level="1"><nlm:affiliation>SKiN Centre for Dermatology and Probity Medical Research, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>SKiN Centre for Dermatology and Probity Medical Research, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kaur, P" sort="Kaur, P" uniqKey="Kaur P" first="P" last="Kaur">P. Kaur</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc, Thousand Oaks, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Philipp, S" sort="Philipp, S" uniqKey="Philipp S" first="S" last="Philipp">S. Philipp</name>
<affiliation wicri:level="3"><nlm:affiliation>Psoriasis Research and Treatment Center, University Hospital Charité, Berlin, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Psoriasis Research and Treatment Center, University Hospital Charité, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Spelman, L" sort="Spelman, L" uniqKey="Spelman L" first="L" last="Spelman">L. Spelman</name>
<affiliation wicri:level="1"><nlm:affiliation>Veracity Clinical Research and Probity Medical Research, Woolloongabba, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Veracity Clinical Research and Probity Medical Research, Woolloongabba, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zhang, N" sort="Zhang, N" uniqKey="Zhang N" first="N" last="Zhang">N. Zhang</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc, Thousand Oaks, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Strober, B" sort="Strober, B" uniqKey="Strober B" first="B" last="Strober">B. Strober</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Connecticut Health Center and Probity Medical Research, Farmington, CT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Connecticut Health Center and Probity Medical Research, Farmington, CT</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">The British journal of dermatology</title>
<idno type="eISSN">1365-2133</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">ABP 501, an FDA- and EMA-approved biosimilar, is highly similar to adalimumab in structure, function, and pharmacokinetics.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>Canada</li>
<li>France</li>
<li>Italie</li>
<li>États-Unis</li>
</country>
<region><li>Berlin</li>
<li>Californie</li>
<li>Connecticut</li>
<li>Victoria (État)</li>
<li>Île-de-France</li>
</region>
<settlement><li>Berlin</li>
<li>Melbourne</li>
<li>Paris</li>
</settlement>
<orgName><li>Université de Melbourne</li>
</orgName>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Papp, K" sort="Papp, K" uniqKey="Papp K" first="K" last="Papp">K. Papp</name>
</noRegion>
<name sortKey="Gooderham, M" sort="Gooderham, M" uniqKey="Gooderham M" first="M" last="Gooderham">M. Gooderham</name>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Bachelez, H" sort="Bachelez, H" uniqKey="Bachelez H" first="H" last="Bachelez">H. Bachelez</name>
</region>
</country>
<country name="Italie"><noRegion><name sortKey="Costanzo, A" sort="Costanzo, A" uniqKey="Costanzo A" first="A" last="Costanzo">A. Costanzo</name>
</noRegion>
</country>
<country name="Australie"><region name="Victoria (État)"><name sortKey="Foley, P" sort="Foley, P" uniqKey="Foley P" first="P" last="Foley">P. Foley</name>
</region>
<name sortKey="Spelman, L" sort="Spelman, L" uniqKey="Spelman L" first="L" last="Spelman">L. Spelman</name>
</country>
<country name="États-Unis"><region name="Californie"><name sortKey="Kaur, P" sort="Kaur, P" uniqKey="Kaur P" first="P" last="Kaur">P. Kaur</name>
</region>
<name sortKey="Strober, B" sort="Strober, B" uniqKey="Strober B" first="B" last="Strober">B. Strober</name>
<name sortKey="Zhang, N" sort="Zhang, N" uniqKey="Zhang N" first="N" last="Zhang">N. Zhang</name>
</country>
<country name="Allemagne"><region name="Berlin"><name sortKey="Philipp, S" sort="Philipp, S" uniqKey="Philipp S" first="S" last="Philipp">S. Philipp</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004C06 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 004C06 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:28755394
   |texte=   Clinical Similarity of the Biosimilar ABP 501 Compared With Adalimumab After Single Transition: Long-Term Results From a Randomised, Double-Blind, 52-Week, Phase 3 Study in Moderate-to-Severe Plaque Psoriasis Patients.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i   -Sk "pubmed:28755394" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Clinical Similarity of the Biosimilar ABP 501 Compared With Adalimumab After Single Transition: Long-Term Results From a Randomised, Double-Blind, 52-Week, Phase 3 Study in Moderate-to-Severe Plaque Psoriasis Patients.

Clinical Similarity of the Biosimilar ABP 501 Compared With Adalimumab After Single Transition: Long-Term Results From a Randomised, Double-Blind, 52-Week, Phase 3 Study in Moderate-to-Severe Plaque Psoriasis Patients.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki